CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals or presented at major oncology conferences.
  • Recall ongoing trials in breast, gastrointestinal, genitourinary, lung and select hematologic cancers, and refer appropriate patients for participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in the individualization of care for patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Identify shared and unique toxicities of newly approved agents, and develop a plan to monitor, manage and mitigate these side effects.
  • Refine or validate existing cancer treatment algorithms on the basis of new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Neeraj Agarwal, MD
  Professor of Medicine
  Senior Director for Clinical Research Innovation
  Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
  Director, Center of Investigational Therapeutics
  Director, Genitourinary Oncology Program
  Huntsman Cancer Institute, University of Utah
  Salt Lake City, Utah
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc.
  
  Tanios Bekaii-Saab, MD
  Professor, Mayo Clinic College of Medicine and Science
  Program Leader, Gastrointestinal Cancer
  Mayo Clinic Cancer Center
  Consultant, Mayo Clinic in Arizona
  Chair, ACCRU Research Consortium
  Phoenix, Arizona
  
  Advisory Committee: Immuneering Corporation, Imugene, Sun Biopharma; Consulting Agreements (to Institution): Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Foundation Medicine, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sobi, Stemline Therapeutics Inc, Treos Bio, Xilis; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, FibroGen, Kintor, Lilly, Pancreatic Cancer Action Network; Inventions/Patents: WO/2018/183488, WO/2019/055687.
  
  Kristen K Ciombor, MD, MSCI
  Assistant Professor of Medicine
  Division of Hematology/Oncology
  Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee
  
  Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Merck, Natera Inc, Pfizer Inc; Consulting Agreements: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Incyte Corporation, Merck, NuCana, Pfizer Inc.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  Director, Lymphoma Program
  Siteman Cancer Center
  St Louis, Missouri
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc.
  
  Mark Levis, MD, PhD
  Professor of Oncology
  Co-Division Director, Hematologic Malignancies
  The Sidney Kimmel Comprehensive Cancer Center
  Johns Hopkins University
  Baltimore, Maryland
  
  No relevant conflicts of interest to disclose.
  
  Ann Partridge, MD, MPH
  Vice Chair of Medical Oncology
  Director, Program for Young Women with Breast Cancer
  Director, Adult Survivorship Program
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Travel Support: Novartis.
  
  Mark D Pegram, MD
  Susy Yuan-Huey Hung Endowed Professor of Oncology
  Director, Clinical and Translational Research Unit
  Associate Dean for Clinical Research Quality
  Stanford University School of Medicine
  Associate Director for Clinical Research
  Stanford Comprehensive Cancer Institute
  Stanford, California
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Dr Mark Pegram’s contribution to this publication was as a paid consultant and was not part of his Stanford University duties or responsibilities.
  
  Daniel P Petrylak, MD
  Professor of Internal Medicine (Medical Oncology) and Urology
  Yale School of Medicine
  New Haven, Connecticut
  
  Consulting Agreements: Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc; Contracted Research: Gilead Sciences Inc.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Amgen Inc, bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, GlaxoSmithKline, Immuneel Therapeutics, Janssen Biotech Inc.
  
  David Sallman, MD
  Assistant Member
  Malignant Hematology
  Moffitt Cancer Center
  Tampa, Florida
  
  Advisory Committee: AbbVie Inc, Aprea Therapeutics, Bristol-Myers Squibb Company, Intellia Therapeutics, Kite, A Gilead Company, Novartis, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc; Consulting Agreements: Magenta Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Incyte Corporation, Servier Pharmaceuticals LLC.
  
  Lecia V Sequist, MD, MPH
  Director, Center for Innovation in Early Cancer Detection
  Massachusetts General Hospital Cancer Center
  The Landry Family Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.
  
  David R Spigel, MD
  Chief Scientific Officer
  Thoracic Oncology
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Consulting Agreements (to Institution): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Curio Science, EMD Serono Inc, Evidera, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Intellisphere LLC, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics, Molecular Templates, Novartis, Novocure Inc, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme; Contracted Research (to Institution): Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Apollomics Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BIND Therapeutics Inc, BioNTech AG, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Denovo Biopharma, Eisai Inc, Elevation Oncology, EMD Serono Inc, Evelo Biosciences Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Grail Inc, Hutchison MediPharma, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kronos Bio, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Merck, Molecular Partners, Molecular Templates, Nektar, Neon Therapeutics, Novartis, Novocure Inc, OncXerna Therapeutics Inc, Pfizer Inc, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Transgene, UT Southwestern Medical Center, Verastem Inc.
  
  Saad Zafar Usmani, MD, MBA
  Chief of Myeloma Service
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine, Weill Cornell Medical College
  New York, New York
  
  Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Mundipharma, Oncopeptides, Sanofi Genzyme, Seagen Inc, Secura Bio, SkylineDx, Takeda Pharmaceuticals USA Inc, TeneoBio; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seagen Inc, SkylineDx, Takeda Pharmaceuticals USA Inc; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Sanofi Genzyme.
  
  Andrew D Zelenetz, MD, PhD
  Medical Director, Quality Informatics
  Attending Physician
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Cultura e Eventos LTDA, Curio Science, DAVA Oncology, Debiopharm, Gilead Sciences Inc, Instituto de Ciências Integradas, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, MEI Pharma Inc, MorphoSys, Oncopeptides, Ono Pharmaceutical Co Ltd, Quant Health, Sandoz Inc, a Novartis Division, Suzhou Liangyihui Network Technology Co Ltd, Vaniam Group, Verastem Inc; Contracted Research: AbbVie Inc, BeiGene Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, MEI Pharma Inc, MethylGene Inc; Data and Safety Monitoring Board/Committee: BeiGene Ltd (DMC Chair), Bristol-Myers Squibb Company, Celgene Corporation, Juno Therapeutics, a Celgene Company; Scientific Advisory Board Chair: Lymphoma Research Foundation; Other: NCCN (B-Cell Lymphoma Panel Chair).
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Merck, Natera Inc, Novartis, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc and Sanofi Genzyme, Sanofi Genzyme, Seagen Inc, Taiho Oncology Inc and Takeda Pharmaceuticals USA Inc.
  
  Release date: November 2021
  Expiration date: November 2022